Get the Daily Brief
Latest Biotech News
Altesa closes $75M Series B to push antivirals into COPD trials
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral that targets rhinovirus, into larger COPD‑focused clinical testing. The round, led by Forbion with...
Korsana emerges with $175M to pursue Alzheimer’s brain‑shuttle antibody
Korsana Biosciences launched from stealth with $175 million to develop KRSA‑028, an antibody engineered to cross the blood‑brain barrier and clear amyloid plaques. The Boston company’s financing...
Guardant ramps screening push — Shield demand and MetaSight buy
Guardant Health set 2026 guidance forecasting a major ramp in Shield screening volumes and disclosed the acquisition of MetaSight Diagnostics to expand its cancer screening portfolio. Executives...
Danaher to buy Masimo — diagnostics M&A accelerates
Danaher agreed to acquire Masimo for approximately $9.9 billion in cash, a deal aimed at broadening Danaher’s acute‑care diagnostics and patient monitoring footprint. The acquisition reflects...
Novartis to sell India generics arm to PE — keeps R&D presence
Novartis agreed to sell its 70.68% stake in Novartis India Limited to a private equity consortium for about $159 million while retaining a separate commercial and R&D footprint in the country. The...
Roche gets FDA decision date for SERD giredestrant; leadership shuffle
Roche announced an FDA target action date of Dec. 18 for giredestrant, its investigational oral SERD for ER‑positive, HER2‑negative breast cancer, based on Phase 3 data showing progression‑free...
MULTI‑evolve and lab‑in‑loop frameworks speed complex protein design
Researchers introduced MULTI‑evolve, an ML‑guided, lab‑in‑the‑loop platform that accelerates the directed evolution of multi‑mutant proteins by combining protein language models, targeted...
Galleri misses primary goal—Grail shares plunge after NHS trial
Grail reported that its NHS‑Galleri multicancer early detection (MCED) trial did not meet the study’s primary endpoint of a statistically significant reduction in stage III–IV cancers. The topline...
FDA formalizes one‑trial default: approval bar lowered as NEJM piece sets tone
FDA leaders published a New England Journal of Medicine perspective stating the agency will adopt a new default that a single well‑controlled clinical trial can serve as the pivotal basis for drug...
Guardant buys MetaSight—screens set to scale with Shield guidance
Guardant Health disclosed the $59 million upfront acquisition of MetaSight Diagnostics and offered ambitious 2026 screening guidance tied to its Shield colorectal cancer screening test. Management...
Danaher moves on Masimo: $10B takeover to bulk up diagnostics and monitoring
Danaher agreed to acquire Masimo in a roughly $10 billion cash deal aimed at strengthening its acute‑care monitoring and diagnostics portfolio. The acquisition will fold Masimo’s pulse oximetry...
Japan backs first iPSC drugs—conditional clearances eyed under CEA pathway
Japan’s regulatory advisory committee recommended conditional approvals for two induced pluripotent stem cell (iPSC)‑derived therapies — Amchepry (Sumitomo/Racthera) and Reheart (Cuorips) — under...
Novartis to sell India generics unit—PE takeover for $159M
Novartis announced plans to transfer its 70.68% holding in Novartis India Limited to a private‑equity consortium in a deal valued at about $159 million, while retaining separate commercial and R&D...
Ionis halts Alzheimer’s program for people with Down syndrome
Ionis Pharmaceuticals confirmed it has stopped development of an investigational Alzheimer’s candidate intended for people with Down syndrome. The company said the decision followed an internal...
Korsana emerges with $175M to back Alzheimer’s shuttle antibody program
Korsana Biosciences surfaced from stealth with $175 million in financing to develop KRSA‑028, a blood‑brain‑barrier shuttle monoclonal antibody targeting amyloid‑beta. The Boston‑based startup...
Element launches Vitari—aims $100 30X genome with high‑throughput platform
Element Biosciences announced Vitari, a new high‑throughput sequencing platform that the company says can produce roughly 3 terabytes per run and sequence a 30X human genome for $100 in 36 hours....
Insilico and Lilly outline 'prompt‑to‑drug' vision—AI‑first R&D framework revealed
Researchers from Insilico Medicine and Eli Lilly published a framework in ACS Central Science describing a pathway toward fully autonomous, AI‑driven 'prompt‑to‑drug' discovery — integrating...
Grail’s Galleri test flops -- shares halve after UK trial misses endpoint
Grail reported that its large NHS-backed trial of the Galleri multicancer early detection (MCED) blood test failed to meet the study’s primary endpoint of a statistically significant reduction in...
FDA formalizes one‑trial default: regulators shift approval bar
Top FDA officials published a New England Journal of Medicine perspective making a single well‑controlled pivotal trial the agency’s new “default” standard for drug approvals, while asking...
Japan backs first iPSC drugs: conditional approvals advance regenerative therapies
Japan’s regulatory advisory panel recommended conditional approvals for two induced pluripotent stem cell (iPSC) therapies—Amchepry (raguneprocel) and Reheart—under the country’s conditional early...